CN105640792B - Dihydromyricetin is in beauty except the application in spot product - Google Patents
Dihydromyricetin is in beauty except the application in spot product Download PDFInfo
- Publication number
- CN105640792B CN105640792B CN201610081044.0A CN201610081044A CN105640792B CN 105640792 B CN105640792 B CN 105640792B CN 201610081044 A CN201610081044 A CN 201610081044A CN 105640792 B CN105640792 B CN 105640792B
- Authority
- CN
- China
- Prior art keywords
- parts
- bletilla
- dihydromyricetin
- product
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/736—Chitin; Chitosan; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Abstract
The present invention relates to a kind of dihydromyricetins and bletilla polysaccharide compatibility to have effects that beauty removes the compounding side of spot, take 30 35 DEG C of distilled water of 200mL that 8 grams of r aminobutyric acids are added, 10 grams of chitosans are added after to be dissolved, add 80 grams of bletilla polysaccharides, it is eventually adding 8 grams of dihydromyricetins, it is deoxygenated by ultrasonication and accelerates dissolving, vacuum drying is made its water content be reduced to 25%, saved backup using vacuum packaging.This method makes full use of r aminobutyric acids and bletilla polysaccharide can be obviously promoted the solubility of dihydromyricetin, but chitosan can guarantee the film-forming feature of product again simultaneously, is also conducive to the stability of dihydromyricetin.
Description
Technical field：
Belong to the technology of natural drug application except the application in spot product in beauty the present invention relates to a kind of dihydromyricetin
Field.
Background technology
Bletilla (Bletilla striata), also known as give free of charge, Lian Jicao, purple blue root, it is orchid family bletilla category perennial herb
Plant, 18~60cm of plant height.Bletilla pseudobulb is conventional Chinese medicine, and hemostasis convergence, detumescence and promoting granulation effect are good.It is used as medicine to take orally and cures mainly lung
Tuberculous hemoptysis, bronchiectasis hemoptysis, gastric ulcer haematemesis, hematuria, the diseases such as have blood in stool；Traumatic hemorrhage, burn and scald, brothers' chap are controlled in external application
It splits.Bletilla chemical constitution study concentrates on bibenzyl, dihydro phenanthrene class and Lian Fei class compounds in bulb in recent years, separated
Identify a series of active bibenzyls, dihydro phenanthrene class and Lian Fei class noval chemical compounds.
Mucilaginous substance in bletilla pseudobulb contains abundant Glucomannan, and content accounts for the 30% of mucilaginous substance total amount, with bletilla
The form of glue exists and the most important effective component of bletilla.The physicochemical property of bletilla glue and Arabic gum, tragacanth class
Seemingly, but stickiness is special.Bletilla haemostatic effect is definitely reliable, related with contained a large amount of bletilla glue.Bletilla glue film forming has relatively strong viscous
Attached power spreads on the blutpunkte or face of animal, can be merged at once with the surface of a wound and be difficult to remove, and is only the one side for contacting wound
It dissolves, thus can stop blooding rapidly and prevent from infecting.Shorten the clotting time it is demonstrated experimentally that Pseudobulbus Bletillae (Rhizoma Bletillae) extract has, inhibit human body
Effect to cellulose dissolution can quickly form artificial thrombus, have preferable treatment to trauma hemostasis or visceral hemorrhage clinical treatment
Effect, it is safe and without any side effects.Bletilla main function is to preserve based on moisture of skin, have the function that skin-active.
Dihydromyricetin is that ampelopsis grossdentata is also known as one of main active ingredient of vine tea, is civil traditional medication, once
It is widely used in treating the infectious diseases such as skin disease, furuncle and osteomyelitis, acute lymphoblastic inflammation, a variety of harmful levels of pathogens can be inhibited.
The time of occurrence of dihydromyricetin energy significantly delaying skin chloasma and senile plaque, solubility is 4% in 25 DEG C of water, in hot water
Solubility bigger；It is soluble in methanol, ethyl alcohol and acetone, it is atomic to be dissolved in ethyl acetate；It is insoluble in chloroform, petroleum ether.Lin Shuying etc.
DMY stability and influence factor are investigated, it was demonstrated that dihydromyricetin solution easily aoxidizes, and stability is poor, not
More than 100 DEG C, heating time is no more than 30min and acid and neutrallty condition can keep its steady chemical structure, and transition state
Metal ion Al3+, Fe3+, Cu2+Play inducing catalysis Deng to the oxidation of dihydromyricetin.
R- aminobutyric acids are inhibitory neurotransmitters critically important in central nervous system, it is a kind of naturally occurring non-
Protein groups have extremely important physiological function at amino acid, it can promote the reactivity of brain, brain tonic and intelligence development, anti-epileptic to promote
Sleep, beauty moisturizing delay brain aging function, can supplement human body inhibitory neurotransmitter, have good blood pressure reduction effect.Promote
Into kidney Fitness improvement and protective effect.
Currently, dihydromyricetin and bletilla polysaccharide are all single use in each product, since dihydromyricetin is water-soluble
Property not high and stickiness it is not strong, the problems such as directly coating skin functionality is not strong, and dihydromyricetin is more easy to aoxidize.
Invention content
Therefore, in order to make full use of the drug action of dihydromyricetin and bletilla polysaccharide, sleep quality is improved, utmostly
The stability of the reservation dihydromyricetin on ground preferably prevents dihydromyricetin from aoxidizing and carrying by polysaccharide molecule package action
Its high stickiness, a kind of bletilla polysaccharide of present invention proposition and dihydromyricetin medicine compatibility method, along with the reinforcing of r- aminobutyric acids is made
To improve sleep quality, bletilla polysaccharide can form thin film in skin surface, and water imbibition is stronger, has skin moisture-keeping effect
Fruit.Since bletilla polysaccharide molecule itself is smaller, it can directly be absorbed by skin, the metabolism of skin can be promoted, reach living
The effect of skin in the presence of bletilla polysaccharide, can reduce two although removing chloasma and antibacterial effect are apparent not as good as dihydromyricetin
The touch opportunity of hydrogen myricetin and oxygen.
Therefore, first purpose of the invention, which is to provide a kind of bletilla polysaccharide, with dihydromyricetin compatibility there is beauty to remove spot work(
The compounding side of effect：A certain amount of water is taken, r- aminobutyric acids are added, wherein r- aminobutyric acids weight g is 1 with water volume mL ratios：2~
8, chitosan is added after dissolving, adds bletilla polysaccharide, is eventually adding dihydromyricetin, is accelerated by ultrasonication deoxidation molten
Solution, vacuum drying are made its water content be reduced to 10~30%, are saved backup using vacuum packaging.
In one embodiment, beauty is made of each raw material composition with following parts by weight except spot product：Bletilla polysaccharide
2~8 parts of 20~60 parts, 2~8 parts of dihydromyricetin, 2~8 parts of chitosan and r- aminobutyric acids.
In a specific embodiment, wherein each material composition is formed with following parts by weight：30~50 parts of bletilla polysaccharide,
2~5 parts of 3~6 parts of dihydromyricetin, 2~5 parts of chitosan and r- aminobutyric acids.
In another embodiment, wherein each material composition is formed with following parts by weight：40 parts of bletilla polysaccharide, two
4 parts of 4 parts of hydrogen myricetin, 5 parts of chitosan and r- aminobutyric acids.
The dihydromyricetin, chitosan and r- aminobutyric acids are directly bought from market, it is desirable that and dihydromyricetin cellulose content >=
98%, r- Gamma-propalanine content >=98%, chitosan content >=98%.
In another specific preparation beauty except in spot product step：Take the 30-35 DEG C of distilled water of 200mL that 8 grams of r- ammonia are added
Base butyric acid is added 10 grams of chitosans after to be dissolved, adds 80 grams of bletilla polysaccharides, be eventually adding 8 grams of dihydromyricetins, by super
Sonicated deoxidation accelerates dissolving, vacuum drying so that its water content is reduced to 25%, saved backup using vacuum packaging.
Second purpose of the invention is to provide a kind of preparation method of bletilla polysaccharide, and it is removed spot product for beauty
In, step includes：
(1) dry bletilla is crushed, after 10~30min of petroleum ether and stirring is added, 1~3 small layered removal is stood and contains stone
The upper solution of oily ether obtains precipitation I.
(2) 80-90% ethanol waters are added into precipitation I, after 30~80min is extracted in stirring, stand 50~140min,
Upper solution of the layering removal containing ethyl alcohol, obtains precipitation II.
(3) a certain amount of water is added into precipitation II, is heated with stirring to 70-85 DEG C, after keeping the temperature 30~80min, 5000rpm
10~20min is centrifuged, supernatant is obtained, goes to precipitate.
(4) supernatant is concentrated under reduced pressure into certain volume at 50-65 DEG C, adds 95% ethyl alcohol to final concentration and reaches
75% or more, alcohol precipitation 10-20h are filtered, and it is bletilla polysaccharide to obtain filter residue.
In one embodiment, petroleum ether described in step (1) is the petroleum ether using 90~120 DEG C of boiling range specifications,
Its volume L is 2~4 with bletilla weight kg ratios：1.
In one embodiment, the volume L of 80-90% ethanol waters described in step (2) and bletilla weight kg ratios
It is 2~5：1.
In one embodiment, it is 2~4 that the volume L of water and bletilla weight kg ratios are added described in step (3)：1.
In one embodiment, certain volume described in step (4) refers to the 1/10-1/40 of original volume.
In one embodiment, it is filtered described in step (4)：Membrane aperture is that 0.22 μm of ceramic membrane filter is primary.
Technique effect
1, it makes full use of r- aminobutyric acids and bletilla polysaccharide that can be obviously promoted the solubility of dihydromyricetin, but protects again simultaneously
The pH value slant acidity of its solution is demonstrate,proved, the stability of dihydromyricetin is also conducive to.
Though 2, material therefor of the present invention all has skin-active effect, mutually effect is more notable after collaboration, and fully profit
It is stronger with the water imbibition of bletilla polysaccharide, make the touch opportunity of dihydromyricetin and oxygen again while playing skin moisturization
It reduces.
3, the present invention utilizes bletilla polysaccharide part fixed function, accelerates dihydro under the conditions of adequate water and r- aminobutyric acids
Repair of the myricetin to skin promotes wound healing effect.
4, film-formation result bacteriostasis can be enhanced by adding chitosan, while the Water-saving effect of product can be reached again.
Specific implementation mode
In the following, the present invention will be further detailed with embodiment, but its any for being not limited to these examples
A or similar example.
Embodiment 1：The preparation method of bletilla polysaccharide
Dry bletilla 100kg is crushed, after being directly added into the petroleum ether and stirring 20min of 200L, 1 small layered removal is stood and contains
The upper solution for having petroleum ether obtains precipitation I；80% ethanol water of 250L is added into precipitation I, after 70min is extracted in stirring,
60min is stood, upper solution of the layering removal containing ethyl alcohol obtains precipitation II.300L water is added into precipitation II, is heated with stirring to
80 DEG C, after keeping the temperature 40min, 5000rpm centrifuges 20min, obtains supernatant, goes to precipitate.Supernatant is concentrated under reduced pressure at 50-65 DEG C
To the 1/25 of original volume, adds 95% ethyl alcohol to final concentration and reach 75% or more, alcohol precipitation 10-20h, carry out 0.22 μm of pottery
Porcelain membrane filtration is primary that filter residue is bletilla polysaccharide product.It is measured through anthrone-sulphate method, soluble sugar content exists in product
99.5% or more.
Embodiment 2：Beauty removes the preparation of spot product
It takes 35 DEG C of distilled water of 200mL that 8 grams of r- aminobutyric acids are added, 10 grams of chitosans is added after to be dissolved, add 80
Gram bletilla polysaccharide, is eventually adding 8 grams of dihydromyricetins, is deoxygenated by ultrasonication and accelerates dissolving, and vacuum drying keeps its aqueous
Amount is reduced to 20%, obtains beauty and removes 115 grams of spot product, and saved backup using vacuum packaging, 1 gram of sample is taken to be examined through HPLC methods
The content for surveying dihydromyricetin is 6.92%.
Comparative examples 1
The bletilla polysaccharide that 35 DEG C of distilled water of 200mL are added 80 grams is taken to add 8 grams after bletilla polysaccharide is completely dissolved
Dihydromyricetin, can not be completely dissolved under ul-trasonic irradiation, need to be heated to 80 DEG C dissolving after vacuum drying make its water content
It is reduced to 20%, 104 grams of obtained product, and saved backup using vacuum packaging, take 1 gram of sample to detect dihydro poplar through HPLC methods
The content of syphilis is 7.34%.
Embodiment 3：Beauty removes the preparation of spot product
It takes 35 DEG C of distilled water of 400mL that 12 grams of r- aminobutyric acids are added, 10 grams of chitosans is added after to be dissolved, add
100 grams of bletilla polysaccharides are eventually adding 12 grams of dihydromyricetins, are deoxygenated by ultrasonication and accelerate dissolving, and vacuum drying makes it
Water content is reduced to 15%, obtains beauty and removes 138 grams of spot product, and saved backup using vacuum packaging, takes 1 gram of sample through HPLC
The content that method detects dihydromyricetin is 8.65%.
Embodiment 4：Inhibiting effect of the various products to tyrosinase activity
After various sample 50g are placed a period of time under the conditions of 37 DEG C, 1 gram of sample is taken to detect dihydromyricetin through HPLC methods
The content of element is shown in Table 1.Dihydromyricetin cellulose content decrease speed is most fast in product obtained by comparative examples 1, up to 23.43%, and
It is 8.23%~10.06% though dihydromyricetin cellulose content has decline in products obtained therefrom of the present invention, relatively low.
Embodiment 5：Use the therapeutic effect of the product
Suggested use and dosage：After first cleaning face when use, its product is directly attached to face affected part, once two days.Clinic examination
Use observations：Test of cure 20 altogether, wherein man 8, female 12, freckle patient 13, butterfly macules patient 7, the age is most
20 years old small, 55 years old maximum, the course of disease is most 2 years short, longest 20 years.Diagnostic criteria：According to patient before experiment in hospital dermatology department, surgery
It is diagnostic criteria through doctor's clinical diagnosis result, face freckle, butterfly macules.Therapy：Patient first cleans face, directly will
Its product is attached to face affected part, once two days, most Low doses 3 months, the longest course for the treatment of 5 months.Criterion of therapeutical effect：External application medicament of the present invention
Afterwards, facial spot all disappears to cure；Spot is reduced, and is reduced to effectively, and nothing substantially change as invalid (poor).
Interpretation of result：20, wherein butterfly macules patient 7 are tested in total, and freckle patient 13, male 8, women 12
Example, through external application product of the present invention, most Low doses 3 months, the longest course for the treatment of 5 months, total effective rate 90%, cure rate 85%, in vain
10%.It is as follows to cure some of cases：
Rattan member, gender female, 32 years old, face suffered from butterfly macules, 8 years, through external application medicament of the present invention, adheres to constantly according to method, 3
The moon is cured.
Jiang Zhongcheng, gender man, 25 years old, facial freckle 6 years, through external application medicament of the present invention, 3 half a months cured.
Wang Ming, female 30 years old, suffer from freckle 20 years, and spot is covered with face, and considerable distress is brought to spirit.By the agency of receives this
Invention drug therapy, 2 months take effect, after with, 3 months cure.
Claims (9)
1. a kind of beauty removes spot product, it is characterised in that：A certain amount of water is taken, r- aminobutyric acids, wherein r- aminobutyric acids is added
Weight g is 1 with water volume mL ratios：2~8, chitosan is added after dissolving, adds bletilla polysaccharide, is eventually adding dihydromyricetin,
It is deoxygenated by ultrasonication and accelerates dissolving, vacuum drying makes its water content be reduced to 10~30%, is preserved using vacuum packaging
It is spare, wherein each raw material composition is formed with following parts by weight：20~60 parts of bletilla polysaccharide, 2~8 parts of dihydromyricetin, chitosan 2
~8 parts and 2~8 parts of r- aminobutyric acids.
2. beauty as described in claim 1 removes spot product, it is characterised in that each raw material composition is formed with following parts by weight：Bletilla
2~5 parts of 30~50 parts of polysaccharide, 3~6 parts of dihydromyricetin, 2~5 parts of chitosan and r- aminobutyric acids.
3. beauty as described in claim 1 removes spot product, it is characterised in that each raw material composition is formed with following parts by weight：Bletilla
4 parts of 40 parts of polysaccharide, 4 parts of dihydromyricetin, 5 parts of chitosan and r- aminobutyric acids.
4. the product as described in one of claims 1 to 3, it is characterised in that the preparation process of the bletilla polysaccharide includes：
(1) dry bletilla is crushed, after 10~30min of petroleum ether and stirring is added, 1~3 small layered removal is stood and contains petroleum ether
Upper solution, obtain precipitation I；
(2) 80-90% ethanol waters are added into precipitation I, after 30~80min is extracted in stirring, stand 50~140min, layering
The upper solution containing ethyl alcohol is removed, precipitation II is obtained；
(3) a certain amount of water is added into precipitation II, is heated with stirring to 70~85 DEG C, after keeping the temperature 30~80min, 5000rpm from
10~20min of the heart, obtains supernatant, goes to precipitate；
(4) supernatant is concentrated under reduced pressure into certain volume at 50~65 DEG C, adds 95% ethyl alcohol to final concentration and reaches 75%
More than, alcohol precipitation 10-20h is filtered, and it is bletilla polysaccharide to obtain filter residue.
5. product as claimed in claim 4, it is characterised in that petroleum ether described in step (1) is to use 90~120 DEG C of boiling ranges
The petroleum ether of specification, volume L are 2~4 with bletilla weight kg ratios：1.
6. product as claimed in claim 4, it is characterised in that the volume L of 80-90% ethanol waters described in step (2) with
Bletilla weight kg ratios are 2~5：1.
7. product as claimed in claim 4, it is characterised in that the volume L and bletilla weight of water are added described in step (3)
Kg ratios are 2~4：1.
8. product as claimed in claim 4, it is characterised in that step filters described in (4)：The ceramics that membrane aperture is 0.22 μm
Membrane filtration is primary.
9. the beauty as described in one of claims 1 to 3 removes spot product, which is characterized in that be directly used in various patient's beauty materials
In application in material or in terms of being directly used in cosmetics except spot or the medical material for inhibiting various pathogens.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610081044.0A CN105640792B (en) | 2016-02-04 | 2016-02-04 | Dihydromyricetin is in beauty except the application in spot product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610081044.0A CN105640792B (en) | 2016-02-04 | 2016-02-04 | Dihydromyricetin is in beauty except the application in spot product |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105640792A CN105640792A (en) | 2016-06-08 |
| CN105640792B true CN105640792B (en) | 2018-08-10 |
Family
ID=56488351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610081044.0A Active CN105640792B (en) | 2016-02-04 | 2016-02-04 | Dihydromyricetin is in beauty except the application in spot product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105640792B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007122251A2 (en) * | 2006-04-25 | 2007-11-01 | Symrise Gmbh & Co. Kg | Synergistic mixture of glycosyl flavanones and xanthines |
| CN101380281A (en) * | 2008-09-26 | 2009-03-11 | 中华全国供销合作总社南京野生植物综合利用研究院 | Paeonol bletilla striata polysaccharide clathrate and preparation technique and use thereof |
| CN105232350A (en) * | 2015-11-05 | 2016-01-13 | 浙江中医药大学 | Water mask and making method thereof |
-
2016
- 2016-02-04 CN CN201610081044.0A patent/CN105640792B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007122251A2 (en) * | 2006-04-25 | 2007-11-01 | Symrise Gmbh & Co. Kg | Synergistic mixture of glycosyl flavanones and xanthines |
| CN101380281A (en) * | 2008-09-26 | 2009-03-11 | 中华全国供销合作总社南京野生植物综合利用研究院 | Paeonol bletilla striata polysaccharide clathrate and preparation technique and use thereof |
| CN105232350A (en) * | 2015-11-05 | 2016-01-13 | 浙江中医药大学 | Water mask and making method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 《二氢杨梅素的制备及其对酪氨酸酶的抑制研究》;王小洪;《应用化工》;20121231;第41卷(第12期);第2109-2111页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105640792A (en) | 2016-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105920067A (en) | Sunflower calathide extract containing polysaccharide, flavonoid and alkaloid and preparation method of sunflower calathide extract | |
| CN105663000A (en) | Rhizome bletillae moisturizing gel product and preparation method thereof | |
| CN1814162A (en) | Pulse-promoting large-volume injecta and preparing method | |
| CN105581964A (en) | Product for rejuvenating and beautifying and preparation method thereof | |
| CN115444893B (en) | Uric acid reducing active substance composition and application thereof | |
| CN104997823A (en) | Medicinal composition containing Folium Ginkgo, red yeast rice and panax notoginseng, and preparation thereof | |
| KR100949482B1 (en) | Phamaceutical composition of diabetes mellitus or hypertension using extract of taxus cuspidata and mulberry tree, and mamufacturing method thereof | |
| CN105640792B (en) | Dihydromyricetin is in beauty except the application in spot product | |
| CN101152223B (en) | Use of poplar leaf phenols extract in preparation of medicine for treating cardiovascular disease | |
| CN101804083B (en) | Application of pollen pini and extract thereof in treating inflammatory bowel disease and method for preparing extract | |
| WO2008091064A1 (en) | Composition comprising trachelospermi caulis and pyrola japonica extracts for the treatment and prevention of inflammatory diseases | |
| KR100964603B1 (en) | Phamaceutical composition of diabetes mellitus using extract of taxus cuspidata and mulberry tree, and mamufacturing method thereof | |
| CN108096318A (en) | Treat pharmaceutical composition of cardiovascular and cerebrovascular disease and its preparation method and application | |
| CN112089784A (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating diseases caused by atherosclerosis | |
| CN105640797B (en) | Dihydromyricetin and application of the bletilla polysaccharide composition in beautifying whitening | |
| WO2009135351A1 (en) | The use of the extract of prunus mume for preparation of compositions | |
| CA2512147A1 (en) | Aqueous extract of red vine leave and use thereof for improving blood circulation | |
| KR20070025066A (en) | Herbal composition for treatment and prevention of diabetes and diabetic complications | |
| KR101611966B1 (en) | Production of antlers and medicinal herbs extract for arthritis care medicine | |
| CN108159274A (en) | Application of the bletilla in prophylactic treatment hemorrhoid | |
| CN111568935B (en) | Application of Siberian cocklebur fruit extract in preparation of antitumor drugs | |
| TW201309317A (en) | An extract of plant providing for treating the healing of wounds | |
| CN109939176B (en) | A Chinese medicinal composition for treating diabetes, and its preparation method | |
| CN101176772B (en) | Pharmaceutical composition made of cattail pollen and safflower | |
| CN101744999B (en) | Extraction method for ginseng, ophiopogon root and schisandra chinensis and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20180719 Address after: 410205 Room 601, 6 / F, Changsha CLP software park headquarters, No. 39, Jian Shan Road, Changsha hi tech Development Zone, Hunan, China Applicant after: Changsha Aiyang Medical Technology Co Ltd Address before: 410000 Changsha City, Hunan, Furong Yuan Apartment Building 607 Applicant before: Wang Jing |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |